The Claims:

1. A cell composition comprising a plurality of limbal derived stromal cells, a plurality of limbal derived epithelial cells, thrombin and fibrinogen, wherein the ~~concentration of~~ limbal derived stromal cells and the limbal derived epithelial cells are each present in the cell composition at a concentration ranginges from 4000 to 5000 cells/µL, and wherein the limbal derived stromal cells and the limbal derived epithelial cells are present in the cell composition at a ratio from 1:5 to 5:1.

~~2. The cell composition as claimed in claim 1, wherein limbal derived stromal cells and limbal derived epithelial cells are present in the ratio from 1:5 to 5:1.~~

~~3. The cell composition as claimed in claim 1, wherein thrombin and fibrinogen are present in the ratio from 1:5 to 5:1.~~

~~4~~2. A multilayer cell composition comprising:

a. a first layer comprising a plurality of limbal derived stromal cells and thrombin; and

b. a second layer comprising a plurality of limbal derived epithelial cells and fibrinogen,

wherein the second layer is deposited over the first layer.

3. A multilayer cell composition comprising:

a. a first layer comprising a plurality of limbal derived stromal cells and thrombin; and

b. a second layer comprising a plurality of limbal derived epithelial cells and fibrinogen,

wherein the second layer is deposited over the first layer,

the limbal derived stromal cells and the limbal derived epithelial cells are each present in the composition at a concentration ranging from 4000 to 5000 cells/µL, and the limbal derived stromal cells and the limbal derived epithelial cells are present in the composition at a ratio from 1:5 to 5:1.

~~5. The multilayer cell composition as claimed in claim 4, wherein the concentration of limbal derived stromal cells and limbal derived epithelial cells ranges from 4000 to 5000 cells/µL.~~

~~6. The multilayer cell composition as claimed in claim 4, wherein limbal derived stromal cells and limbal derived epithelial cells are present in the ratio from 1:5 to 5:1.~~

~~7~~4. The multilayer cell composition as claimed in claim ~~4~~2 or 3, wherein the thrombin and the fibrinogen are present in the composition at a ratio ranging from 1:5 to 5:1.

~~8. The cell composition as claimed in any one of claims 1 to 3 or multilayer cell composition as claimed in any one of claims 4 to 7, wherein the limbal derived stromal cells and limbal derived epithelial cells are autologous or allogenic.~~

~~9. The cell composition as claimed in any one of claims 1 to 3 or multilayer cell composition as claimed in any one of claims 4 to 7, wherein the cells are obtained from donor tissue or are differentiated from a stem cell in vitro.~~

~~10. The cell composition as claimed in any one of claims 1 to 3 or multilayer cell composition as claimed in any one of claims 4 to 7, wherein the composition is layered on the corneal or ocular surface of an individual.~~

~~11~~5. A method of preparing a cell composition ~~as claimed in claim 1~~, the method comprising: ~~the step of~~ mixing a plurality of limbal derived stromal cells and a plurality of limbal derived epithelial cells to produce a mixed population of cells; and

adding thrombin and fibrinogen, wherein the ~~ratio of~~ limbal derived stromal cells ~~to~~ and the limbal derived epithelial cells are present in the cell composition at a ratio ranging~~es~~ from 1:5 to 5:1, and the limbal derived stromal cells and the limbal derived epithelial cells are each present in the cell composition at a concentration ranging from 4000 to 5000 cells/µL, and wherein the cell composition is for treating a non-healing corneal epithelial defect or a persistent corneal epithelial defect.

6. The method as claimed in claim 5, further comprising customizing the ratio of limbal derived stromal cells and limbal derived epithelial cells as per the treated defect.

7. The method as claimed in claim 5 or 6, further comprising steps for obtaining the limbal derived epithelial cells and the limbal derived stromal cells, the steps comprising:

harvesting the limbal derived epithelial cells;

removing a portion of the limbal derived epithelial cells; and

differentiating the portion into limbal derived stromal cells.

~~12~~8. A method of preparing a multilayer cell composition ~~as claimed in claim 4~~, the method comprising ~~the steps of~~:

a. depositing a first layer comprising a plurality of limbal derived stromal cells and thrombin; and

b. depositing a second layer comprising a plurality of limbal derived epithelial cells and fibrinogen, wherein the second layer is deposited over the first layer, and

wherein the composition is for treating a non-healing corneal epithelial defect or a persistent corneal epithelial defect.

9. A method of preparing a multilayer cell composition, the method comprising:

a. depositing a first layer comprising a plurality of limbal derived stromal cells and thrombin; and

b. depositing a second layer comprising a plurality of limbal derived epithelial cells and fibrinogen, wherein the second layer is deposited over the first layer, and

wherein the limbal derived stromal cells and the limbal derived epithelial cells are present in the composition at a ratio ranging from 1:5 to 5:1, and the concentration of limbal derived stromal cells and limbal derived epithelial cells are each present in the composition at a concentration ranging from 4000 to 5000 cells/µL, and

wherein the composition is for treating a non-healing corneal epithelial defect or a persistent corneal epithelial defect.

~~13. The method as claimed in claim 12, wherein the concentration of limbal derived stromal cells and limbal derived epithelial cells ranges from 4000 to 5000 cells/µL.~~

~~14. The method as claimed in claim 12, wherein the ratio of limbal derived stromal cells to limbal derived epithelial cells ranges from 1:5 to 5:1.~~

10. The method as claimed in claim 8 or 9, further comprising customizing the ratio of limbal derived stromal cells and limbal derived epithelial cells as per the treated defect.

~~15~~11. The method as claimed in any one of claims ~~12~~8 to 10, wherein the ~~ratio of~~ thrombin ~~to~~ and the fibrinogen are present in the composition at a ratio ranginges from 1:5 to 5:1.

~~16~~12. The method as claimed in any one of claims ~~11~~ 8 to ~~15~~11, wherein the preparation of the multilayer cell composition is performed simultaneously with layering~~ed~~ the composition on ~~the~~a corneal or an ocular surface of an individual with the non-healing corneal epithelial defect or the persistent corneal epithelial defect.

13. The method as claimed in any one of claims 8 to 12, further comprising steps for obtaining the limbal derived epithelial cells and the limbal derived stromal cells, the steps comprising:

harvesting the limbal derived epithelial cells;

removing a portion of the limbal derived epithelial cells; and

differentiating the portion into limbal derived stromal cells.

~~17. A system for delivering a limbal epithelial tissue producing composition to a treatment site in an individual comprising a delivery system, wherein the delivery system comprises the cell composition as claimed in any one of claims 1 to 3 or multilayer cell composition as claimed in any one of claims 4 to 7.~~

~~18. A kit comprising a cell composition as claimed in any one of claims 1 to 3 or multilayer cell composition as claimed in any one of claims 4 to 7 and a delivery system for delivering the cell composition to a treatment site in an individual.~~

~~19~~14. Use of a cell composition as claimed in ~~any one of~~ claim~~s~~ 1 ~~to 3~~, or a cell composition prepared by a method as claimed in any one of claims 5 to 7, or a multilayer cell composition as claimed in any one of claims ~~4~~2 to ~~7~~4, or a multilayer cell composition prepared by a method as claimed in any one of claims 8 to 13 in the manufacture of a medicament for treating a disease or disorder of the eye in a patient, wherein said disease or disorder of the eye is a non-healing corneal epithelial defect or a persistent corneal epithelial defect.

15. The use as claimed in claim 14, wherein the composition is to be layered on a corneal or an ocular surface of the patient.